About Synosia Therapeutics
Synosia Therapeutics is a Healthcare company based in Basel (Switzerland) founded in 2005, and was acquired by Biotie in January 2011. Therapeutics for CNS disorders including Parkinsons are developed. Synosia Therapeutics has raised $91.16 million across 3 funding rounds from investors including UCB, Schroders and Investor. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative.
Company details
Synosia Therapeutics was established in 2005 in Basel, Switzerland, within the biotechnology sector. Focus is placed on developing pharmaceutical candidates for central nervous system disorders. The lead product, SYN-115, an adenosine A2a antagonist, is advanced for Parkinsons disease treatment. Additional candidates are pursued for Alzheimers disease, bipolar disorder, drug dependence, and post-traumatic stress disorder, with operations centered on research and clinical development.
- Headquarters Basel, Switzerland
- Stage Acquired
- SectorsHealthcare
- Website synosia.com
- Acquired by Biotie (Jan 2011)
Funding Insights of Synosia Therapeutics
Synosia Therapeutics has successfully raised a total of $91.16M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $30 million completed in October 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $91.16M
- Total Rounds 3
- Last Round Series C — $30M
- First Round $32.5M
(Jan 2007)
- Investors Count 8
All 3 funding rounds of Synosia Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
9 investors in total: 9 institutional.
Investors in Synosia Therapeutics
Synosia Therapeutics has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include UCB, Schroders and Investor.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com | |||
Venture capital fund backed incubator focused on the healthcare startups | 5amventures.com | San Francisco, United States | ||
Investments are directed by the Wallenberg family into Nordic sectors. | 1916 | investorab.com | Stockholm, Sweden | |
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Growth capital is provided by Aravis for Swiss high-tech companies. | aravis.ch | Switzerland | ||
Early stage venture capital firm investing in US | 1973 | abingworth.com | London, United Kingdom | |
Therapies for immunological and neurological disorders are developed. | 1928 | ucb.com | Brussels, Belgium | |
Investment management and wealth management services are provided to clients. | 1804 | schroders.com | London, United Kingdom | |
Drugs for neurodegenerative and psychiatric disorders are developed by Biotie. | 1998 | biotie.com | Turku, Finland |
Investor details for Synosia Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Synosia Therapeutics
4 dated milestones of Synosia Therapeutics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Synosia Therapeutics is founded.
- Funding First funding round of $32.5M.
- Funding Latest funding round, Series C, of $30.0M.
- Exit Acquired by Biotie.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Synosia Therapeutics
Complete news archive for Synosia Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Synosia Therapeutics
Synosia Therapeutics was founded in 2005 and raised its 1st funding round 2 years after it was founded.
Synosia Therapeutics is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
Synosia Therapeutics is a funded company, having raised a total of $91.16M across 3 funding rounds to date. The company's 1st funding round was a Series A of $32.5M, raised on Jan 2007.
Synosia Therapeutics was established in 2005 in Basel, Switzerland, within the biotechnology sector. Focus is placed on developing pharmaceutical candidates for central nervous system disorders. The lead product, SYN-115, an adenosine A2a antagonist, is advanced for Parkinsons disease treatment. Additional candidates are pursued for Alzheimers disease, bipolar disorder, drug dependence, and post-traumatic stress disorder, with operations centered on research and clinical development.
Synosia Therapeutics has 9 investors. Key investors include UCB, Schroders, Investor, Abingworth, and Biotie.
Yes. Synosia Therapeutics was acquired by Biotie in January 2011.